SpringWorks Therapeutics, Inc.

Biotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

Phase 21

Phase 12

By Therapeutic Area

top 1

Oncology

150%

R&D Momentum

37/100

Pipeline Velocity

11/100

Trial Completion Rate

67/100

Pipeline Concentration

50/100

Pipeline Freshness

81/100

Strategic Signals

↗Active in Oncology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 21, 2026

Available

Individual Patient Compassionate Use of Nirogacestat

Sep 21, 2026

Available

Individual Patient Compassionate Use of Mirdametinib

Sep 16, 2026

Active, not recruiting

A Single-arm, Open-label Phase 2 Study of Nirogacestat in Adult Japanese Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Sep 15, 2026

Recruiting

A Single-Arm, Open-Label Phase 4 Study of Nirogacestat in Adult Premenopausal Females With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Earlier

Sep 3, 2026TrialA Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations

Aug 26, 2026TrialA Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors

Aug 25, 2026TrialA Phase 1 Open-Label Study to Assess the Pharmacokinetics of Mirdametinib and Its Metabolite PD-0315209 in Participants With Impaired Hepatic Function and Participants With Normal Hepatic Function

Aug 21, 2026TrialA Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors

4 more events

Aug 21, 2026TrialA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Jul 11, 2026TrialA Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity

Dec 1, 2025TrialTo Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

Nov 17, 2025TrialTo Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Gomekli13 patentsFeb 17, 2041 Gomekli6 patentsMar 16, 2043 Gomekli4 patentsFeb 4, 2044

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

SW-682Phase 1

Unknown / Other

CAR

Mirdametinib and CarbamazepinePhase 1

Plexiform Neurofibroma

Mirdametinib and CarbamazepinePhase 2

Regulatory

Regulatory Timeline

20231 event

FDANov 27

Ogsiveo — OGSIVEO

Application NDA217677 (NDA)

20252 events

FDAFeb 11

Gomekli — GOMEKLI

Application NDA219389 (NDA)

FDAFeb 11

Gomekli — GOMEKLI

Application NDA219379 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)